Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia.
J Urol. 2013 Jul;190(1):130-6. doi: 10.1016/j.juro.2013.01.014. Epub 2013 Jan 9.
The long-term success rate of dilation and/or internal urethrotomy is low in cases of recurrent urethral stricture. We investigated the ability of the Memokath™ 044TW stent to maintain urethral patency after dilation or internal urethrotomy for recurrent urethral stricture.
A total of 92 patients with recurrent bulbar urethral strictures (mean length 2.7 cm) were treated with dilation or internal urethrotomy and randomized to short-term urethral catheter diversion (29) or insertion of a Memokath 044TW stent (63). The primary end point was urethral patency, as assessed by passage of a calibrated endoscope. Secondary end points included urinary symptoms and uroflowmetry parameters. Stents were scheduled to remain in situ for 12 months.
The rate of successful stent insertion was 93.6% (59 of 63 patients). In stented patients patency was maintained significantly longer than controls (median 292 vs 84 days, p <0.001). Patency was reflected in significantly improved uroflowmetry and symptom scores. The stent was removed in 100% of patients. The most frequently noted side effects in stented patients were bacteriuria, hematuria and penile pain, which were usually mild and transient. There was no difference in sexual function between stented and control patients. Stent dislocation and occlusion were observed in 8 and 3 patients, respectively.
Patients with recurrent bulbar urethral strictures treated with dilation or urethrotomy and a Memokath 044TW stent maintained urethral patency significantly longer than those treated with dilation or urethrotomy alone. The stent side effect profile was favorable. The stent was straightforward to insert and it was removed without difficulty even after long-term placement.
对于复发性尿道狭窄,扩张和/或尿道内切开术的长期成功率较低。我们研究了 Memokath™ 044TW 支架在扩张或尿道内切开术治疗复发性尿道狭窄后的保持尿道通畅的能力。
共 92 例复发性球部尿道狭窄(平均长度 2.7cm)患者接受扩张或尿道内切开术治疗,并随机分为短期尿道导管引流(29 例)或插入 Memokath 044TW 支架(63 例)。主要终点是通过校准内窥镜评估的尿道通畅性。次要终点包括尿症状和尿流率参数。支架计划原位保留 12 个月。
支架插入成功率为 93.6%(63 例患者中的 59 例)。在支架置入患者中,通畅时间明显长于对照组(中位数 292 天 vs 84 天,p<0.001)。通畅性反映在尿流率和症状评分的显著改善。100%的患者取出了支架。支架置入患者最常见的不良反应为菌尿、血尿和阴茎疼痛,通常为轻度和短暂的。支架置入患者和对照组患者的性功能无差异。支架脱位和阻塞分别在 8 例和 3 例患者中观察到。
对于接受扩张或尿道内切开术治疗的复发性球部尿道狭窄患者,与单独接受扩张或尿道内切开术治疗的患者相比,使用 Memokath 044TW 支架治疗可显著延长尿道通畅时间。支架的不良反应谱良好。支架易于插入,即使长期放置,取出也毫不费力。